Jeff Yass’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.05M | Sell |
47,900
-94,800
| -66% | -$1.97M | ﹤0.01% | 8086 |
|
|
2026
Q1 | $3.33M | Sell |
142,700
-119,800
| -46% | -$2.6M | ﹤0.01% | 5055 |
|
|
2025
Q4 | $5.52M | Sell |
262,500
-16,800
| -6% | -$293K | ﹤0.01% | 3861 |
|
|
2025
Q3 | $4.3M | Buy |
279,300
+20,900
| +8% | +$274K | ﹤0.01% | 4338 |
|
|
2025
Q2 | $2.42M | Buy |
258,400
+35,700
| +16% | +$393K | ﹤0.01% | 5382 |
|
|
2025
Q1 | $2.74M | Buy |
222,700
+180,600
| +429% | +$2.55M | ﹤0.01% | 4849 |
|
|
2024
Q4 | $557K | Sell |
42,100
-158,300
| -79% | -$2.71M | ﹤0.01% | 8411 |
|
|
2024
Q3 | $3.86M | Buy |
200,400
+171,000
| +582% | +$3.53M | ﹤0.01% | 4072 |
|
|
2024
Q2 | $604K | Sell |
29,400
-71,300
| -71% | -$1.49M | ﹤0.01% | 7812 |
|
|
2024
Q1 | $2.4M | Sell |
100,700
-47,900
| -32% | -$1.07M | ﹤0.01% | 4950 |
|
|
2023
Q4 | $3.21M | Sell |
148,600
-545,200
| -79% | -$8.38M | ﹤0.01% | 4453 |
|
|
2023
Q3 | $10.1M | Buy |
693,800
+590,800
| +574% | +$11.2M | ﹤0.01% | 2565 |
|
|
2023
Q2 | $2.16M | Buy |
+103,000
| New | +$2.14M | ﹤0.01% | 4999 |
|
|
2023
Q1 | – | Sell |
-73,100
| Closed | -$1.86M | – | 13438 |
|
|
2022
Q4 | $1.86M | Buy |
73,100
+54,800
| +299% | +$1.28M | ﹤0.01% | 4840 |
|
|
2022
Q3 | $440K | Sell |
18,300
-1,500
| -8% | -$33.7K | ﹤0.01% | 8822 |
|
|
2022
Q2 | $381K | Buy |
+19,800
| New | +$330K | ﹤0.01% | 8921 |
|
|
2022
Q1 | – | Sell |
-19,300
| Closed | -$422K | – | 13905 |
|
|
2021
Q4 | $422K | Buy |
19,300
+6,900
| +56% | +$127K | ﹤0.01% | 9619 |
|
|
2021
Q3 | $237K | Sell |
12,400
-54,600
| -81% | -$910K | ﹤0.01% | 11123 |
|
|
2021
Q2 | $1.15M | Sell |
67,000
-35,400
| -35% | -$648K | ﹤0.01% | 7376 |
|
|
2021
Q1 | $2.29M | Buy |
102,400
+9,300
| +10% | +$210K | ﹤0.01% | 5603 |
|
|
2020
Q4 | $2.07M | Buy |
93,100
+57,600
| +162% | +$1.19M | ﹤0.01% | 5022 |
|
|
2020
Q3 | $524K | Sell |
35,500
-54,700
| -61% | -$834K | ﹤0.01% | 7565 |
|
|
2020
Q2 | $1.34M | Buy |
90,200
+74,700
| +482% | +$1.14M | ﹤0.01% | 5272 |
|
|
2020
Q1 | $170K | Sell |
15,500
-89,500
| -85% | -$840K | ﹤0.01% | 8876 |
|
|
2019
Q4 | $922K | Sell |
105,000
-9,000
| -8% | -$66.1K | ﹤0.01% | 5688 |
|
|
2019
Q3 | $852K | Buy |
114,000
+56,000
| +97% | +$510K | ﹤0.01% | 6050 |
|
|
2019
Q2 | $540K | Buy |
+58,000
| New | +$423K | ﹤0.01% | 7100 |
|
|
2019
Q1 | – | Sell |
-14,100
| Closed | -$63K | – | 9770 |
|
|
2018
Q4 | $63K | Sell |
14,100
-39,400
| -74% | -$216K | ﹤0.01% | 8403 |
|
|
2018
Q3 | $432K | Buy |
53,500
+7,800
| +17% | +$55.6K | ﹤0.01% | 6801 |
|
|
2018
Q2 | $321K | Buy |
45,700
+18,300
| +67% | +$180K | ﹤0.01% | 7702 |
|
|
2018
Q1 | $390K | Buy |
+27,400
| New | +$291K | ﹤0.01% | 7144 |
|
Other funds holding SNDX
KCM
DM
EP
HRCM
Jeff Yass's SNDX Position: Q2 2026 in Review
Jeff Yass increased its Syndax Pharmaceuticals (SNDX) stake by 131% in Q2 2026, buying an estimated $5.35M and bringing the position to 454,101 shares worth $9.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3425.
Jeff Yass first reported a position in SNDX in Q3 2018 and has held it in 26 quarters since. The position peaked at $17.5M in Q1 2024. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- Jeff Yass held 454,101 shares of Syndax Pharmaceuticals worth $9.93M as of Q2 2026.
- Jeff Yass bought 257,480 Syndax Pharmaceuticals shares in Q2 2026, an estimated $5.35M.
- Syndax Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3425 holding.
- Jeff Yass first reported a position in Syndax Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
- Jeff Yass's Syndax Pharmaceuticals position peaked at $17.5M in Q1 2024.
- 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.